Exact Sciences Corp
Company Profile
Business description
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a noninvasive stool-based DNA test, is a precancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
Contact
5505 Endeavor Lane
MadisonWI53719
USAT: +1 608 284-5700
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
6,600
Exact Sciences Corp News & Analysis
etfs
ARK Innovation ETF has likely been a disappointment for most investors
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,680.50 | 27.80 | 0.32% |
| CAC 40 | 7,826.73 | 55.78 | 0.72% |
| DAX 40 | 21,258.38 | 216.38 | 1.03% |
| Dow JONES (US) | 44,025.81 | 537.98 | 1.24% |
| FTSE 100 | 8,577.62 | 29.33 | 0.34% |
| HKSE | 19,778.77 | 327.78 | -1.63% |
| NASDAQ | 19,756.78 | 126.58 | 0.64% |
| Nikkei 225 | 39,646.25 | 618.27 | 1.58% |
| NZX 50 Index | 13,037.14 | 15.76 | -0.12% |
| S&P 500 | 6,049.24 | 52.58 | 0.88% |
| S&P/ASX 200 | 8,429.80 | 27.40 | 0.33% |
| SSE Composite Index | 3,213.62 | 29.00 | -0.89% |